BofA Securities Raises Liquidia Corporation (LQDA) PT to $37, Reiterates Buy Rating

Liquidia Corporation (NASDAQ:LQDA) is one of the best hot stocks to invest in. On October 9, BofA raised the firm’s price target on Liquidia to $37 from $35 and kept a Buy rating on the shares. BofA previewed Q3 2025 EPS updates for its commercial-stage biopharma coverage and does not expect any major Q3 beats/misses and no big 2026 revisions among the group.

Liquidia reported its Q2 2025 earnings with a strong launch of its product, YUTREPIA (treprostinil inhalation powder). The quarter’s total revenue reached $8.8 million. This was comprised of $6.5 million from YUTREPIA product sales, which began shipping in June, and $2.3 million in service revenue related to a promotion agreement for treprostinil injection with Sandoz.

BofA Securities Raises Liquidia Corporation (LQDA) PT to $37, Reiterates Buy Rating

Commercially, the company has signed contracts with major commercial payers, which is expected to improve market access and remove new-to-market blocks in the coming quarters. However, the initial $6.5 million revenue was attributed primarily to channel inventory, with patient demand expected to drive growth into Q3.

Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company that develops, manufactures, and commercializes various products for unmet patient needs in the US.

While we acknowledge the potential of LQDA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LQDA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.